{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:03:45Z","timestamp":1762113825568,"version":"3.37.3"},"reference-count":16,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To diagnose graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is sometimes difficult. We showed previously that MEK inhibitors selectively suppress murine GVHD while retaining antiviral and antitumor immunity. Here, we asked whether the RAS\/MEK\/ERK pathway is activated in human allo-HSCT recipients with GVHD, and whether the phosphorylated ERK1\/2 can be a biomarker of GVHD. Peripheral blood was sequentially collected from 20 allo-HSCT recipients: 1 bone marrow transplant, 7 peripheral blood stem cell transplants (PBSCT), and 12 cord blood transplants. Ten of the 20 allo-HSCT recipients developed GVHD, and phosphorylation of ERK1\/2 in T and B cells was analyzed by flow cytometry. Occurrence of acute GVHD was associated with phosphorylation of ERK1\/2 in CD4+ T cells at day 30 (P &amp;lt; .001), which was suppressed by ex vivo exposure to a MEK inhibitor trametinib at clinically achievable concentrations. In particular, ERK1\/2 was phosphorylated preferentially in naive\/central memory CD4+ T cells. Notably, phosphorylation of ERK1\/2 fell as GVHD improved. These results suggest that phosphorylation status of ERK1\/2 in peripheral blood CD4+ T cells may be a future biomarker for diagnosing human GVHD, and the potential efficacy of MEK inhibitors against human GVHD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000343","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:41:08Z","timestamp":1582198868000},"page":"667-671","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Phosphorylated ERK1\/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1182","volume":"4","author":[{"given":"Hidekazu","family":"Itamura","sequence":"first","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-6151","authenticated-orcid":false,"given":"Takero","family":"Shindo","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshioka","sequence":"first","affiliation":[{"name":"Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"first","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"issue":"6835","key":"2020022011410216100_B1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/35077251","article-title":"Haematopoietic cell transplantation as immunotherapy","volume":"411","author":"Appelbaum","year":"2001","journal-title":"Nature"},{"issue":"5","key":"2020022011410216100_B2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2020022011410216100_B3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2020022011410216100_B4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020022011410216100_B5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2011-01-330217","article-title":"Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation","volume":"118","author":"Inamoto","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2020022011410216100_B6","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2012-12-476218","article-title":"MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner","volume":"121","author":"Shindo","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020022011410216100_B7","doi-asserted-by":"crossref","first-page":"e86331","DOI":"10.1172\/jci.insight.86331","article-title":"The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects","volume":"1","author":"Itamura","year":"2016","journal-title":"JCI Insight"},{"key":"2020022011410216100_B8","first-page":"355","article-title":"Trametinib attenuates delayed rejection and preserves thymic function in rat lung transplantation","volume-title":"Am J Respir Cell Mol Biol","author":"Takahagi","year":"2019"},{"issue":"8","key":"2020022011410216100_B9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020022011410216100_B10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease","volume":"112","author":"Anderson","year":"2003","journal-title":"J Clin Invest"},{"issue":"5","key":"2020022011410216100_B11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2014.01.032","article-title":"Engineering human peripheral blood stem cell grafts that are depleted of na\u00efve T cells and retain functional pathogen-specific memory T cells","volume":"20","author":"Bleakley","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020022011410216100_B12","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.4049\/jimmunol.179.10.6547","article-title":"Naive and memory T cells induce different types of graft-versus-host disease","volume":"179","author":"Dutt","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"2020022011410216100_B13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbmt.2007.12.004","article-title":"Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients","volume":"14","author":"Shindo","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020022011410216100_B14","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.bbmt.2011.10.019","article-title":"Clinical applications for biomarkers of acute and chronic graft-versus-host disease","volume":"18","author":"Levine","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020022011410216100_B15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/bmt.2012.143","article-title":"Biomarkers for acute GVHD: can we predict the unpredictable?","volume":"48","author":"Chen","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020022011410216100_B16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12185-013-1406-9","article-title":"Graft-versus-host disease biomarkers: omics and personalized medicine","volume":"98","author":"Paczesny","year":"2013","journal-title":"Int J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/4\/667\/1716871\/advancesadv2019000343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/4\/667\/1716871\/advancesadv2019000343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:41:12Z","timestamp":1582198872000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/4\/667\/452518\/Phosphorylated-ERK12-in-CD4-T-cells-is-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000343","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}